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Pneumonia is one of the commonest infections in elderly patients. The pathogens responsible for pneumonias
in the elderly are the same as in younger adults. Because of associated cardiopulmonary disease and/or
impaired host defenses, pneumonia in elderly patients is associated with increased mortality and morbidity
compared to younger patients. The clinical importance of pneumonias in the elderly relates to age-dependent
and pathologic changes in the immune system as well as the lungs. Pneumonias in the elderly may be
classified, for clinical purposes, according to their location of acquisition, i.e. community-acquired
pneumonias, nursing home-acquired pneumonias, or hospital-acquired pneumonias. The clinical
presentation of pneumonias in the elderly may be difficult, due to pre-existing cardiopulmonary disease that
mimics pneumonia. This review discusses the diagnostic and therapeutic approaches to elderly patients
with pneumonia.
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INTRODUCTION
For centuries, pneumonia has often been the terminal infectious
disease event in the elderly. Elderly patients are more predis-
posed to pneumonia because of their impaired gag reflex,
decreased mucociliary function, waning immunity, impaired
febrile response, and various degrees of cardiopulmonary dys-
function. Central nervous system disorders and/or an impaired
gag reflex predispose elderly patients to aspiration pneumonia.
The distribution and extent of aspirated oropharyngeal contents
determine the radiologic appearance, clinical presentation and
severity of the pneumonia in elderly patients. Elderly patients
often have some degree of cardiopulmonary disease that has,
through one or more events during their lifetime, decreased
their heart and lung function. Fever resulting from pneumonia
may further burden an already compromised myocardium,
resulting in congestive heart failure (CHF) and/or myocardial
infarction. Not uncommonly, patients presenting with CHF
have pneumonia-induced fever as the proximate cause of their
cardiac decompensation. Patients with long smoking histories
may have bronchogenic carcinoma, which may predispose to
pneumonia, depending upon extent and location. Post-
obstructive pneumonias due to bronchogenic carcinomas are
most common in the elderly. Patients with chronic bronchitis
resulting from a lifetime of heavy smoking are also predisposed
to pneumonia. Depending upon severity, chronic bronchitics
have degrees of lung damage which may be further exacerbated
by superimposed pneumonia. Such patients often have little
normal lung reserve, and the added insult of bacterial
pneumonia often presents as a severe pneumonia because of
pre-existing anatomic and functional decreases in pulmonary
function.
The elderly also have many underlying systemic disorders
that may predispose to impaired splenic function. Humoral
immunity dependent upon intact B-lymphocyte function may
be decreased in the elderly. Older individuals may have a variety
of systemic disorders that impair splenic function with resultant
loss of antibody production. Impaired B-lymphocyte function
predisposes to infection with encapsulated pathogens that are
common causes of bacterial pneumonia, i.e. Streptococcus pneu-
moniae and Haemophilus influenzae. Infiltrative disorders of the
spleen, conditions that anatomically impinge on splenic blood
supply and systemic conditions associated with impaired splenic
function, e.g. cirrhosis and inflammatory bowel disease, alone
or in combination, may result in an age-dependent decrease in
protective antibody function. Bacteria are the commonest
causes of pneumonia in older individuals. The organisms
affecting the elderly are the same as in young adults, but with
a different age-related distribution. Streptococcus pneumoniae is
still the most important pathogen in younger as well as older
adults. However, H. influenzae is relatively more common in
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elderly patients than in non-elderly adults. Moraxella catarrhalis is
of particular importance as a cause of community-acquired
pneumonia (CAP) in patients with chronic bronchitis. Atypical
pathogens in the elderly are the same as in younger adults but
with a different age-dependent distribution. For example,
Mycoplasma occurs in the elderly but is more common in young
adults. Conversely, legionnaires’ disease is more common in
elderly adults than in younger adults. Chlamydia pneumoniae
occurs in all age groups and in the nursing home setting, but
probably is most common in young adults. Rickettsial and
parasitic pneumonias are relatively rare in immunocompetent
elderly individuals. The most important viral cause of pneu-
monia in the elderly is influenza, which appears in the winter
months and occurs in outbreaks, either in the community or in
chronic-care facilities or hospitals [1–4].
Pneumonias of the elderly may be classified according to how
the infection is acquired, i.e. hematogenously or by primary
inhalation. Aspiration is a variant of pneumonia acquired via
inhalation. Urinary tract infections are not uncommon in
elderly men and may result in urosepsis with secondary hema-
togenous spread to the lungs, resulting in pneumonia. Alter-
natively, pneumonia may be classified according to the patient’s
location when the pneumonia was acquired. Pneumonias
acquired from the community are termed community-acquired
pneumonia, those that are acquired in chronic care facilities or
nursing homes are termed nursing home-acquired pneumonia
(NHAP), and those that are contracted in the hospital are called
hospital-acquired pneumonia (HP). HP is synonymous with
nosocomial pneumonia (NP), a term which is sometimes used
interchangeably with ventilator-associated pneumonia. Clearly,
ventilator-associated pneumonia differs from NP or HP because
the patient is intubated and on a respirator, but is otherwise
equivalent. Pneumonias may also be classified on the basis of the
causative organism. Since organisms pathophysiologically
express themselves in a stereotypical fashion, an etiologic
classification of pneumonia correlates best with the patient’s
signs and symptoms. Pneumococcal pneumonia, whether com-
munity acquired or nursing home acquired, presents in exactly
the same fashion regardless of location, since clinical manifesta-
tions are determined by the microbe and not the location where
the patient’s pneumonia was acquired. Similarly, pneumococcal
pneumonia may manifest itself early during hospitalisation
(hospital day 5), but does not occur later in the hospital
course, i.e. after a week of hospitalisation. So-called NP due to
Streptococcus pneumoniae presenting soon after hospitalisation, in
fact, represents CAP that has become manifest in the first few
days after admission to the hospital. Streptococcus pneumoniae
pneumonia in this setting presents in precisely the same manner
as hospital-acquired pneumococcal pneumonia, since it is the
same clinical entity. Similarly, legionnaires’ disease, whether
presenting as CAP, as NHAP, or in the nosocomial setting, is
accompanied by signs and symptoms referable to Legionella’s
characteristic pattern of extrapulmonary organ involvement
[1–29].
CLINICAL PRESENTAT ION
General concepts
Young adults with pneumonia usually present with fever,
leukocytosis, and an infiltrate on the chest X-ray. Elderly
patients will often have only the infiltrate, which is not always
accompanied by fever or leukocytosis. For this reason, the
diagnosis of pneumonia in the elderly, particularly in patients
with NHAP or NP, depends heavily upon the interpretation of
the chest X-ray, taking into consideration other disorders that
may mimic pneumonia on the chest X-ray. Much has been
written about the radiologic mimics of pneumonia, ranging
from bronchogenic carcinoma, to drug reactions, to CHF.
While systemic diseases with pulmonary manifestations are
always in the differential diagnosis of patients with presumed
pneumonia, systemic conditions are particularly likely to cause
diagnostic confusion in patients with possible NHAP or NP.
Most patients transferred to a hospital from a nursing home,
with pulmonary infiltrates, with or without fever or leukocy-
tosis, have, in fact, CHF. CHF may be an exacerbation of pre-
existing heart failure or may represent myocardial infarction and
associated CHF. Interstitial lung disease, drug-induced disease,
collagen vascular diseases, etc. all need to be taken into account,
in addition to CHF, in the differential diagnosis of pneumonia in
elderly patients.
The majority of elderly patients with pneumonias develop a
productive cough. However, older patients who are dehydrated
or have an impaired ability to cough may have little or no
sputum production. Scant sputum suggests a viral or atypical
pneumonia if all other factors are equal. Productive sputum
does not differentiate an acute exacerbation of chronic bron-
chitis from pneumonia. The best way to differentiate tracheo-
bronchitis or an acute exacerbation of chronic bronchitis from
pneumonia is to obtain a chest X-ray. Patients with pneumonia
should have infiltrates due to the pneumonia; blood-tinged
sputum may occur with a variety of non-infectious diseases, e.g.
pulmonary embolism/infarction, mitral stenosis, and neoplasm,
but may also occur with pneumococcal or Klebsiella pneumonia.
The sputum in legionnaires’disease may be purulent or mucoid
[2,5].
Pastmedical history
The history, in a patient with pneumonia, provides informa-
tion that may suggest the diagnosis of pneumonia or suggest
alternative diagnoses for the patient’s symptoms.
Questioning the patient about recent contacts with other
individuals with a similar illness is particularly useful in
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outbreaks of influenza or NHAP due to C. pneumoniae. If a
patient has recently been discharged from a hospital, then
readmission with pneumonia could suggest either incomplete
resolution of the initial process or that the patient had developed
pneumonia during the previous admission which is now man-
ifesting as a nosocomial pneumonia. History of contact with
younger individuals with respiratory illnesses may suggest
mycoplasma pneumonia in the elderly. Often, Mycoplasma
pneumoniae is not considered in the differential diagnosis, solely
because of the patient’s age. Elderly patients are visited by
younger individuals and visit younger individuals frequently.
Students may be home from school, or there may be contact
with neighbors or friends with young children, and unless this
avenue is explored in elderly patients with a mycoplasma-like
illness, mycoplasma or C. pneumoniae pneumonia may be not
sufficiently considered in the differential diagnosis. Similarly,
contact with psittacine birds may suggest psittacosis. Elderly
patients often have pets, but most pets, while capable of
transmitting a variety of infectious diseases, do not usually
harbor pathogens commonly associated with pneumonias. A
history of strokes or dementia may predispose the patient to
repeated episodes of aspiration pneumonia. Impaired gag reflex
and a wide variety of esophageal disorders may also predispose
the patient to repeated episodes of aspiration pneumonia,
whether acquired in the community, nursing home, or hospital.
Patients with pre-existing lung disease, particularly those with
chronic bronchitis, are predisposed to exacerbations of chronic
bronchitis as well as pneumonia. Such patients have a long
previous history of heavy smoking that predisposes them to
pneumonia, heart failure, and bronchogenic carcinoma. A
history of recurrent pneumonia may be coincidental, or if there
is a physio-anatomic reason for the repeated aspiration, e.g.
central nervous system or esophageal disease, then repeated
bouts of pneumonia are to be expected. Patients with systemic
lupus erythematosus (SLE), those with multiple myeloma, those
with chronic lymphatic leukemia (CLL), those with early HIV
and alcoholics are all predisposed to contracting pneumonias
caused by encapsulated organisms, e.g. Streptococcus pneumoniae
and H. influenzae [30–32].
Most elderly patients who have survived into late adulthood
do not have immunodeficiency problems predisposing them to
contracting pneumonia. Patients with cystic fibrosis infre-
quently survive to old age. In contrast, those with bronchiectasis
often reach the later decades of life. Patients with repeated
pneumonias from the same anatomic location may have a partial
endobronchial obstruction. Recurrent pneumonias in the same
anatomic location should suggest an underlying bronchogenic
carcinoma presenting with repeated episodes of post-obstruc-
tive pneumonia that do not fully clear, or that recur frequently
in the same location [1–3].
It is as important to obtain a pertinent medical history of
cardiac and lung conditions that may mimic pneumonia as it is
to ascertain the factors that predispose to pneumonia in the
elderly. Particularly important in the elderly is a history of
interstitial lung disease, regardless of etiology. Comparing pre-
vious films with current chest films will usually clarify the
etiology of the pulmonary infiltrates. A history of collagen
vascular diseases, e.g. rheumatoid arthritis or SLE, may explain
infiltrates and/or pleural effusions seen on the chest X-ray. A
previous history of radiation to the mediastinum may suggest
radiation pneumonitis as the cause of an abnormal chest film. A
detailed medication history is useful, as it may reveal drugs that
may cause pulmonary fibrosis, pleural effusions, pulmonary
infiltrates, interstitial lung disease and non-cardiac pulmonary
edema. A cardiac history is as important as a pulmonary history,
because of the frequency of CHF in elderly patients. Patients
may have an exacerbation of pre-existing heart failure, or may
have heart failure due to an acute coronary event. Worsening of
pre-existing CHF may occur with coronary or valvular heart
disease. In addition to the history, the chest X-ray should reveal
cardiomegaly, with or without pleural effusion, and there
should be signs of CHF present on the physical examination.
CHF is the diagnosis most likely to mimic pneumonia in elderly
patients. The history should look for factors predisposing to
pulmonary embolus or infarction, which may also mimic
pneumonia in elderly patients. A careful history may reveal
prolonged stasis secondary to confinement or prolonged travel.
Malignancies associated with a hypercoagulable state may also
predispose the patient to pulmonary emboli. Other systemic
diseases may also directly or indirectly affect the lungs. Scler-
oderma may decrease esophageal motility predisposing to
aspiration pneumonia, and cause interstitial lung disease
mimicking pneumonia. A history should prompt questions
relevant to disorders that predispose to pneumonia [30–33].
Physical examination
Physical examination of the chest reveals adventitious sounds
over the area of pneumonia. Loud, tubular breath sounds
suggest copious secretions in the large bronchi, and are not
diagnostic of pneumonia per se, but may accompany pneumo-
nia. Dullness at the bases may be reflective of carcinoma, CHF,
pleural effusion due to carcinoma or an intra-abdominal pro-
cess, or a bacterial pneumonia. Bilateral pleural effusions are
rarely, if ever, due to an infectious etiology. Bilateral pleural
effusions should suggest CHF as the most likely diagnostic
possibility. Legionnaires’ disease may also present with a uni-
lateral pleural effusion. Among the bacterial pneumonias, most
frequently H. influenzae presents with a mild to moderate
pleural effusion. Pneumococcal pneumonia and klebsiella
pneumonia more often present with empyema rather than
pleural effusion, but the clinical presentation, in terms of
auscultation of the chest, would be the same. Dullness may
also be reflective of consolidation over the involved lobe of the
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lung. Consolidative pneumonias may occur with any of the
pathogens and are not specific for any particular etiologic agent
[1,2,8,12,19,27–29].
The physical findings associated with influenza are minimal.
Because influenza is an interstitial process, the auscultation of
the chest is silent in primary influenza pneumonia. If rales are
heard, especially if they are localised to one segment or lobe in a
patient with viral pneumonia, then there is a superimposed
bacterial pneumonia also present. In mycoplasma pneumonia,
there is a discrepancy between the clinical findings, e.g. aus-
cultatory findings, and the appearance on chest X-ray, which
may be a clue to the diagnosis. C. pneumoniae pneumonia has no
pathognomonic findings on physical examination, and resem-
bles mycoplasma pneumonia closely in clinical presentation,
except for the added presence of laryngitis. Laryngitis may be
caused by one of many respiratory viruses, but these viruses do
not usually cause viral pneumonia in elderly adults. The asso-
ciation of pneumonia and laryngitis should suggest C. pneumo-
niae pneumonia until proven otherwise, since hoarseness is a
feature with C. pneumoniae pneumonia but not M. pneumoniae
pneumonia [1–4].
Laboratory tests
As previously mentioned, the chest X-ray is essential to rule out
conditions that may mimic pneumonia and confirm the pre-
sence of pneumonia. Other findings on the chest X-ray may
have important diagnostic significance, e.g. the anatomic dis-
tribution of the lesion, the appearance of the lesion, whether
the process is alveolar or interstitial, whether the process is
confined to perihilar or peripheral regions, or whether the
infiltrates are confined to segments or lobes or ignore the
anatomic segments of the lungs. All elderly patients with
pneumonias should have blood cultures and a full blood count
in addition to the chest X-ray. Other tests should be ordered as
suggested by elements of the history, physical examination or
chest X-ray [5,6].
If an atypical pneumonia is suspected, then serum glutamic-
oxaloacetic transaminase, serum glutamate pyruvate transami-
nase, alkaline phosphatase and serum phosphorus should be
obtained. Patients with productive cough should have a Gram
stain and culture of expectorated sputum. Patients with chronic
bronchitis need not have their sputum Gram stained or cul-
tured, since results invariably show normal flora or mixed flora,
which is unhelpful in establishing a specific etiologic diagnosis.
For specific pathogens, acute and convalescent titers should be
requested, depending upon the pattern of organ distribution
and the presence or absence of relative bradycardia. Specific
serological investigations may be requested for Legionella, Myco-
plasma pneumoniae, or C. pneumoniae. Separate IgM and IgG
titers, not simply a chlamydia titer, should be requested. If
Mycoplasma is suspected, then cold agglutinin titers may be
ordered, which are most likely to be elevated early in the course
of the illness. A cold agglutinin titer of64 is most likely due to
mycoplasma cold agglutinins rather than to viruses or other
systemic disorders associated with elevations of cold agglutinins.
Specific C. pneumoniae IgM and IgG titers should be ordered. If
chlamydia titers are requested, the laboratory may respond with
a combined IgM/IgG result, which is unhelpful, or with a C.
trachomatis titer. If there is psittacine bird contact, then acute and
convalescent titers for C. psittaci may be obtained. Convalescent
titers should preferably be obtained 6–8 weeks after the acute
titers. Clinicians should remember that all patients do not
mount an antibody response, and antimicrobial therapy may
blunt or delay convalescent titers. Increases in the serum
transaminases may suggest legionnaires’ disease, or alternatively
CHF due to passive congestion of the liver, or infiltrate of liver
disease, which may also be affecting the lungs. Microscopic
hematuria in elderly men should suggest benign prostatic
hypertrophy (BPH), but if otherwise unexplained in the patient
with pneumonia, should suggest legionnaires’ disease. Legion-
naires’ disease may also be diagnosed by direct fluorescent
antibody (DFA) staining of the sputum, which has a relatively
low yield, but provides immediate confirmation of the diagnosis
when positive. DFA positivity for Legionella in the sputum
decreases rapidly after the initiation of appropriate antimicrobial
therapy. Therefore, DFA should be obtained from patients
suspected of having legionnaires’ disease with purulent sputum,
as soon as possible after admission, and preferably before anti-
microbial therapy is initiated. In patients where Legionella is
suspected, the legionella urinary antigen test may be of use.
Legionella antigenuria may take a week or two to become
positive, but persists for many months even after resolution of
legionella pneumonia. Legionella antigenuria is most helpful as
a retrospective confirmatory test, but has limited usefulness
early on in the illness. The other limitation of the legionella
antigen test is that it is positive only for L. pneumophila serogroup
1 and is not positive for other L. pneumophila serogroups or
the many non-L. pneumophila species that cause legionnaires’
disease. The clinician should order other tests that will be
helpful in ruling out non-infectious disorders mimicking pneu-
monias as suggested by the history and physical examination
[5–7].
Serial chest X-rays are important in evaluating the efficacy of
the patient’s therapy or lack of response, which may indicate
inappropriate antimicrobial therapy or a non-infectious disease
mimic of pneumonia. After the initial chest X-ray, a repeat chest
X-ray 3–5 days after the initiation of appropriate antimicrobial
therapy is most helpful. If the patient has begun to improve,
repeat chest X-rays are usually not necessary unless the patient
fails to resolve completely, or the pneumonia worsens or recurs.
Abnormalities on the chest X-ray may persist, particularly with
pneumococcal pneumonia, for months after clinical deferves-
cence. Repeated chest X-rays are not necessary as long as the
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patient has clinically defervesced and a second film has shown
interval improvement.
If influenza is suspected, the virus may be cultured from the
nose or oropharyngeal secretions, or diagnosed by serologic
means. Outbreaks of C. pneumoniae pneumonia in nursing
homes are best diagnosed serologically using specific IgM
and IgG C. pneumoniae titers obtained acutely and during the
convalescent period [1–4].
ANTIMICROBIAL THERAPY
General considerations
The selection of empirical antimicrobial therapy for pneumonia
acquired in the community, nursing home or hospital depends
on adequate coverage of the presumed pathogens. However,
before antimicrobial therapy is selected, other considerations
need to be taken into account. Patients should be questioned
regarding drug allergies, particularly reactions to penicillin and
sulfonamides. Patients with a history of penicillin allergy should
be questioned as to the nature of the allergy, to determine if it
was an anaphylactoid or non-anaphylactoid reaction. Patients
who give a vague history of penicillin allergy, or who manifest
their allergy with fever or a maculopapular rash, may be given
b-lactam antibiotics. Those with anaphylactoid reactions should
not be treated with b-lactam antibiotics but may be treated with
doxycycline, fluoroquinolones, monobactams, or carbapenems.
Except for trimethoprim–sulfamethoxazole, none of the other
commonly used antibiotics for pneumonias contain sulphon-
amide moieties.
Elderly patients often have various degrees of liver and
hepatic function, which are important in antibiotic selection
and dosing. Patients with advanced liver disease may need to
have antibiotics that are hepatically eliminated and inactivated
decreased in terms of daily dose. Alternatively, the pneumonia
may be treated with antibiotics that are eliminated or inactivated
primarily via the renal route. Since there are no good tests of
liver function, as exist for renal function, the clinician must
make a clinical judgment in decreasing the dose of hepatically
eliminated antimicrobials. Mild to moderate hepatic insuffi-
ciency can usually be treated safely with drugs that are primarily
hepatically eliminated or inactivated [34,35].
If the antibiotic selected to treat an elderly patient with
pneumonia is eliminated primarily via the renal route, then
the daily dose should be decreased in proportion to the decrease
in renal function. Since the creatinine in elderly patients may
not reflect renal function, the dosage adjustments of renally
eliminated antibiotics should be based on measurements or
estimates of the creatinine clearance. If a patient’s creatinine
clearance is half that of normal individuals, then the daily
dose should be decreased by about half. Dosing adjustments
may be achieved by either decreasing the dose and maintaining
the dosing interval, or by maintaining the dose and increasing
the dosing interval, or by decreasing the dose and increasing the
dosing interval such that the daily dose is decreased proportio-
nately to the creatinine clearance. In patients with severe renal
insufficiency approaching anuria, dose adjustments may be
made on the basis of the creatinine clearance, or alternatively,
an antibiotic of the appropriate spectrum which is primarily
hepatically eliminated or inactivated may be used instead. In
treating patients on dialysis, it is important to note whether the
patient is on chronic ambulatory peritoneal dialysis or hemo-
dialysis, since antibiotics are not removed equally in each type of
dialysis process. Many clinicians prefer to use antibiotics that are
not removed by dialysis, thus eliminating the need for complex
calculations. Clinicians should consult standard references
on dosing antimicrobials in dialysis, or obtain an infectious
disease or renal consultation to assist them with guidance in
dosing specific drugs in patients using peritoneal dialysis or
hemodialysis [33,34].
Elderly patients often have poor venous access, making
intravenous therapy, particularly in nursing home patients,
difficult. Patients admitted to the hospital with CAP, or devel-
oping pneumonia within the hospital, can be treated intrave-
nously, since venous access can usually be obtained by central
line or by cut down, if necessary. In the past, the intramuscular
route of administration has been relied upon, particularly in
chronic-care facilities, where lack of intravenous teams and the
difficulties of placing intravenous lines in elderly patients are
problems. Except for aminoglycosides and ceftriaxone, most
antibiotics used for pneumonias should not be administered
intramuscularly. Since elderly patients often have very decreased
muscle mass, it is difficult and uncomfortable for patients to
receive antimicrobial therapy via this route [5,30,34].
Because of the difficulties with intravenous and intramuscular
administration of antimicrobials, there has been an increasing
reliance recently on treating patients with pneumonias totally or
partially with oral antibiotics. Patients with nosocomial pneu-
monias continue to be treated for most, if not all, of their course
with intravenous antibiotics. In contrast, patients with CAP
who are admitted to the hospital are usually started on empirical
antimicrobial therapy with an intravenously administered anti-
biotic, and patients who defervesce after 48 h are switched to an
equivalent oral antibiotic.
There has been a great increase in the introduction of
intravenous to oral switch programs in hospitals to treat pneu-
monias as well as other infectious diseases. Intravenous to
oral switch programs have important pharmacoeconomic
advantages for the healthcare system, and important advantages
for the patient in the hospital. Oral antimicrobial therapy
eliminates the need for venous access and may permit
earlier patient discharge from the hospital. By decreasing or
eliminating intravenous antibiotics, the frequency of phlebitis
associated with intravenous therapy is all but eliminated. The
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pharmacokinetic advantages of earlier discharge of patients
recovering from pneumonia with oral antimicrobial therapy
should not be underestimated, as the savings are profound. Oral
antimicrobial therapy is not only important in the treatment of
hospitalised patients with CAP but is particularly important for
patients with pneumonia in chronic care facilities. NHAP
patients are the group that benefits most from oral antimicrobial
therapy. The personnel in nursing homes are not as readily
available as personnel in the hospital setting. The main patient
population is elderly and has limited muscle mass and poor
venous access. Treating NHAP completely by the oral route has
several advantages for the patient. Early oral antibiotic treatment
of a NHAP may permit the patient to remain in the nursing
home and complete the course of therapy there. Early treatment
of NHAP may prevent the patient from having to be transferred
to a tertiary-care facility for hospitalisation, which may be
unnecessary if oral antimicrobial therapy is initiated in the
chronic-care facility [30–36](Table 1).
Selection of empirical antibiotic therapy
Empirical antimicrobial therapy should be based on the
presumed pathogens, which differ according to the site of
acquisition of the patient’s pneumonia. Clinicians should be
familiar with the most likely pathogens to be encountered
in patients with CAP, NHAP, or NP, in order to select
an antimicrobial with the appropriate spectrum. Optimal
antimicrobial therapy neither misses important pathogens
nor provides excessive coverage of known or non-existent
pathogens [37,38].
The pathogens responsible for CAP are Streptococcus pneumo-
niae, H. influenzae, and Moraxella catarrhalis. K. pneumoniae is an
additional consideration in those with alcoholic cirrhosis.
Enterobacter, Serratia, Acinetobacter and Pseudomonas aeruginosa
need not be included in empirical coverage for elderly patients
with CAP. Community-acquired aspiration pneumonia is due
to the aspirated anaerobic oropharyngeal flora. The anaerobes
above the waist, including those of the oropharyngeal flora, do
not require anti-Bacillus fragilis coverage, and are usually sensi-
tive to most antibiotics selected for treating pneumonias. While
aspiration pneumonia is an important clinical entity, with its
attendant mortality and morbidity, it is not an important
therapeutic consideration. Approximately 85% of CAPs are
due to the typical bacterial pathogens cited above and, depend-
ing upon geographic region, the remaining 15% may be caused
by the atypical pathogens, e.g. Legionella, Mycoplasma, or C.
pneumoniae. Legionella and C. pneumoniae are the most common
causes of atypical pneumonias in the elderly, and Mycoplasma
pneumoniae is relatively less common in this age group [6]. Most
clinicians prefer to cover both typical and atypical pathogens
with an empirical antimicrobial antibiotic. Since most elderly
patients are taking multiple medications, polypharmacy is
a potential problem in terms of drug–drug interactions
[3,6,34,37–39].
Table1 Causes of pneumonia in the elderly
Episodic
Pathogens
(certain groups) Outbreaks
Community-acquired pneumonia (CAP) Viral influenza
Typical (85%) Streptococcus pneumoniae Klebsiella pneumoniae
Haemophilus influenzae (chronic alcoholics)
Moraxella catarrhalis
Oral anaerobes
Atypical (15%) Legionella Staphylococcus aureus
Mycoplasma (only postviral influenza,
Chlamydia pneumoniae otherwise not a case of CAP)
Nursing home-acquired Streptococcus pneumoniae Oral anaerobes Influenza
pneumonia (NHAP) Haemophilus influenzae (aspiration pneumonias) Chlamydia pneumoniae
Moraxella catarrhalis
Legionella
Oral anaerobes
Nosocomial pneumonia (NP) Pseudomonas aeruginosa Acinetobacter
NP is not usually due to
Staphylococcus aureus
(MSSA/MRSA), enterococci
(Enterococcus faecalis, Enterococcus faecium),
Stenotrophomonas
maltophilia, Burkholderia
cepacia, Citrobacter, or
Enterobacter
Aerobic gram-negative
organisms
Legionella
MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus.
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Since combination therapy is not better than monotherapy,
monotherapy is preferred on the basis of lower cost and
simplicity. Combination therapies that have been used to treat
CAP include a third-generation cephalosporin, usually ceftriax-
one, plus doxycycline or a macrolide. In parenteral regimens,
erythromycin or azithromycin have been used most frequently
in combination with ceftriaxone. Ceftriaxone, doxycycline or a
respiratory quinolone are popular monotherapy regimens. Cef-
triaxone used alone is effective against all of the typical patho-
gens, but misses the atypical pathogens. Ceftriaxone has no oral
equivalent limiting its application to intravenous to oral switch
programs. Macrolides should not be used as monotherapy in
treating CAP, because approximately 20% of strains of Strepto-
coccus pneumoniae are resistant to all macrolides. Doxycycline is
available intravenously and orally, and is effective against both
typical and atypical pathogens. Both ceftriaxone and doxycy-
cline are effective against most strains of penicillin-resistant
Streptococcus pneumoniae. The respiratory quinolones are quino-
lones that are highly active against both the typical and atypical
respiratory pathogens causing CAP. Because ciprofloxacin is
relatively inactive against Streptococcus pneumoniae, even though
it is active against the atypical pathogens, it is not termed a
‘respiratory quinolone’. Levofloxacin is the first of the respira-
tory quinolones and the one that has been used most exten-
sively. At the present time, other respiratory quinolones, e.g.
gatifloxacin, are equivalent to levofloxacin in their activity
against both typical and atypical pathogens, as well as most
strains of penicillin-resistant pneumococci. Respiratory quino-
lones are ideal in intravenous to oral switch programs. Because
their bioavailability is so high, e.g. 99–100% for levofloxacin,
these antibiotics are ideal not only for intravenous to oral switch
programs, but also in the treatment of CAP and NHAP when
used as sole agents orally [36–39].
Since the pathogen distribution of NHAP most closely
resembles CAP, NHAP should be treated in the same way as
CAP. Empirical coverage in NHAP should be directed against
Streptococcus pneumoniae, H. influenzae, or Moraxella catarrhalis. As
with CAP, aspiration pneumonia, a common cause of NHAP,
may be treated with any of the monotherapy or combination
therapy regimens mentioned above. Because oral monotherapy
has advantages in HP, doxycycline or a respiratory quinolone are
ideal agents for the treatment of NHAP. The inability to achieve
intravenous access, or delays in achieving access, frequently
result in the transfer of patients with NHAP to hospitals for the
treatment of their pneumonias. The early administration of
appropriate oral antibiotics in NHAP has the advantage of
treating the pneumonia as early as possible, and may remove
the need to transfer the patient to a tertiary-care facility [10–12].
Nosocomial pneumonias are caused by aerobic Gram-nega-
tive bacilli found in the hospital environment. Coverage is
usually directed against P. aeruginosa, because it is the most
invasive organism causing pneumonia in the hospital setting.
Necrotising pneumonia due to P. aeruginosa is not common but
is associated with high mortality and morbidity. Antibiotics that
are effective against P. aeruginosa are usually effective against the
other aerobic Gram-negative bacilli that may cause HPs, e.g.
Escherichia coli, K. pneumoniae, or Serratia marcescens. Appropriate
empirical therapy may be accomplished in several ways,
depending upon the presence or absence of P. aeruginosa as a
likely pathogen. If the patient presents with a necrotising
pneumonia characterised by rapid cavitation in the chest X-
ray and a fulminant clinical course, then most clinicians prefer
double antipseudomonal drug coverage. Other popular regi-
mens include an empirical double-drug antipseudomonal for
the usual 14-day course of therapy, regardless of the etiology of
the NP. Alternatively, some centers prefer to initiate therapy
with double antipseudomonal drug coverage and discontinue
one antibiotic after 72 h, if Pseudomonas is not apparent clinically
or isolated from the blood. Another approach has been to
initiate therapy with a single antipseudomonal antibiotic, and
add a second antipseudomonal antibiotic if Pseudomonas
becomes clinically apparent or is grown from the bloodstream
after 72 h. Fourteen days is the usual duration of therapy,
regardless of the regimen selected [15,18,40,41].
Nosocomial aspiration pneumonia is due to aspirated oro-
pharyngeal secretions that have been colonised by aerobic
Gram-negative bacilli during the first week of the hospital stay.
These aspirated oropharyngeal contents contain anaerobic
organisms, as in the case of community-acquired aspiration
pneumonia, but, in addition, contain aerobic Gram-negative
bacilli from the hospital environment. Since anaerobic organ-
isms are not an important therapeutic consideration in aspira-
tion pneumonia, the therapy of nosocomial pneumonia,
whether due to aspiration or not, should be directed against
aerobic Gram-negative bacilli and not anaerobic organisms, just
as in CAP or NHAP aspiration pneumonia [16,23].
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